Navigation Links
Genmab Announces HuMax-CD32b Pre-Clinical Program
Date:1/4/2008

Summary: Genmab has Announced a New Pre-Clinical Antibody Program Called

HuMax-CD32b.

COPENHAGEN, January 4 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today a new pre-clinical antibody program called HuMax-CD32b(TM). This fully human IgG1,k antibody targets the CD32b receptor found on immune cells and hematological tumors. HuMax-CD32b may have therapeutic potential in the treatment of B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma, Burkitt's lymphoma, follicular lymphoma and diffuse large B-cell lymphoma.

The lead candidate for HuMax-CD32b was selected from a panel of over 60 antibodies based on its excellent selectivity and binding ability for the CD32b target and potent triggering of the immune system killing mechanism antibody-dependent cellular cytotoxicity (ADCC). The antibody was highly effective in suppressing tumor growth in in vivo mouse tumor models in which tumor growth was monitored by highly sensitive bioluminescence imaging.

In animal models, HuMax-CD32b has been shown to induce impressive anti-tumor responses. The CD32b receptor has an inhibitory role on immune cells and blockade of CD32b has been documented to strongly potentiate the therapeutic effects of other anti-tumor antibodies. An antibody targeting CD32b may thus be attractive for combination therapy with other antibodies.

"We believe HuMax-CD32b has great potential as a cancer therapeutic, both because of its impressive anti-tumor activity, and the potential for combination with other therapeutic antibodies, such as antibodies directed to CD20 or CD38." said Prof. Jan G. J. van de Winkel, Ph.D., Chief Scientific Officer at Genmab A/S.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using unique, cutting-edge antibody technology, Genmab's world class discovery and development t
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Files IND for Second Genmab Antibody
2. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
3. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
4. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
5. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
6. Genmab Announces Results for the First Nine Months of 2007
7. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
8. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
9. Genmab A/S - Company Announcement
10. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
11. Genmab Announces Asset Exchange Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
(Date:9/29/2014)... at the forefront of diagnostics today, with imaging ... tomography), scanning, and NMR (nuclear magnetic resonance) increasing ... problems of image resolution and quality still limit ... tissue. A solution is hyperpolarization, which involves injecting ... quality by following the distribution and fate of ...
(Date:9/29/2014)... conflicts in Iraq and Afghanistan, more than 300,000 soldiers ... injury caused by exposure to bomb blasts and ... Symptoms of traumatic brain injury can range from the ... severe impairments in memory and cognition. , Since ... critical importance and complexity of this problem, and has ...
(Date:9/29/2014)... Va. , Sept. 29, 2014  Ten ... the fields of cartilage repair, regeneration, allograft reconstruction ... from around the world gathered to discuss the ... Health Institute of Regenerative Medicine symposium, Cartilage ... . Topics included Orthopedic Biosurgery, Minced Juvenile Allograft, ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... Dendreon Corporation,(Nasdaq: DNDN ) today announced ... NEUVENGE, an investigational active cellular immunotherapy, in the,August ... The article highlights,the safety profile, immune response and ... cancer who have failed standard,therapy. "In addition ...
... Inc., a biotechnology company developing pharmaceutical products for ... dollar financing deal. The majority of the funding, ... the remainder was borrowed from the Madison Development ... Funds, a private investment firm. The funds raised ...
... more than a marketing campaign and the involvement of ... managers, senior executives and middle managers responsible for creating ... play a vital role in marketing the brand. Employees ... work. , ,Be Your Message. Employer brand building ...
Cached Biology Technology:Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4Quintessence Secures Financing 2Quintessence Secures Financing 3Employer Brands Require More Than Slick Marketing 2
(Date:9/29/2014)... A University of Texas at Arlington research team says ... built in their lab could open doors for homeland ... be published in the Oct. 1 issue of ... and his co-authors describe a new method to fabricate ... and oxygen until a transparent ceramic is formed. ...
(Date:9/29/2014)... has received a five-year, $6 million grant for ... evaluation and development of safe and effective treatments ... from the National Institutes of Health, National Institute ... for Medication Development for Cocaine Use Disorder to ... guide decisions on moving forward with more expensive ...
(Date:9/29/2014)... For decades, planetary geologists have speculated that glaciers ... 2000-mile-long chasm that constitutes the Grand Canyon of ... that might have been carved by past glaciers ... observations have remained highly controversial and contested. ... College and the Freie Universitaet Berlin has identified ...
Breaking Biology News(10 mins):UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3New VCU center to target cocaine addiction 2Glaciers in the Grand Canyon of Mars? 2Glaciers in the Grand Canyon of Mars? 3Glaciers in the Grand Canyon of Mars? 4Glaciers in the Grand Canyon of Mars? 5Glaciers in the Grand Canyon of Mars? 6Glaciers in the Grand Canyon of Mars? 7Glaciers in the Grand Canyon of Mars? 8Glaciers in the Grand Canyon of Mars? 9
... (Santa Barbara, Calif.) An international team of researchers ... that happens in virtually every cell of our bodies. ... folded chains of amino acids assume their specific shapes, ... widely: In the human body, proteins fold to become ...
... family history of liver cancer is reported to increase risk ... findings published in the May issue of Hepatology , ... Liver Diseases. The study also shows 70-fold elevated risk of ... markers for hepatitis B (HBV) or hepatitis C (HCV). ...
... Princeton University researchers have observed a self-degradation response to ... provide new answers to lingering questions among scientists about ... that depression is not solely linked to the neurotransmitter ... PLoS ONE , researchers based in the lab of ...
Cached Biology News:In protein folding, internal friction may play a more significant role than previously thought 2Family history of liver cancer increases risk of developing the disease 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 2Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 3Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression 4
... ChIP-on-chip Microarray is specifically designed for ... DNA binding proteins by pairing chromatin ... This set delivers robust hybridization and ... binding events and fewer false positives. ...
... White solid.. PACKAGED UNDER INERT GAS. Cyclizes ... is "driven" to completion. A protective agent for ... in many other preparations. Blocks the lethal and ... titration. Contaminants: Heavy metals: ≤1 ppm. ...
... genomics-based research with S. aureus, Sigma-Genosys has developed ... primers to amplify all open reading frames (ORFs) ... are included to amplify ORFs that are unique ... S. aureus. The ORFmer set contains primers to ...
... LabX light balance makes your life easier. It offers ... and management for one balance. *Instruments supported: ... AX, MX, UMX, AG, XS, XP, PR, SR, PG-S, ... *Job management: User ...
Biology Products: